TABLE 1.
Gene | SARS‐coV2‐lung | Thalidomide or lenalidomide treatment |
---|---|---|
AKT1, AKT2 | Upregulation | Signalling—Down 36 , 37 |
ANGPTL4 | Upregulation | Down 38 |
CDC42 | Upregulation | Down 39 |
COL1A1* | Upregulation | Down 15 |
COL1A2* | Upregulation | Down 40 |
MMP2 | Upregulation | Down 41 |
THBS2* | Upregulation | Down (present study) |
VEGFA | Upregulation | Down 42 , 43 |
VEGFC | Upregulation | Down 42 , 43 |
FGF2* | Upregulation | Down 7 , 43 |
FLT1 | Upregulation | Down 44 |
FN1 | Upregulation | Down 45 |
HIF1A | Upregulation | Down 46 |
IGF1 | Upregulation | Down 7 |
MMP14 | Upregulation | Down 41 |
RBPJ | Upregulation | Down 47 |
TIMP1 | Upregulation | Down 36 , 37 |
VCAM1 | Upregulation | Down 38 |
IFN‐γ | Upregulation | Down 39 |
IL‐6 | Upregulation | Down 15 |
HGF | Upregulation | Down 39 |
IL‐10 | Upregulation | Down 41 |
IL‐1β | Upregulation | Down 48 |
CTNNB1* | Upregulation | Down 41 , 43 |
MCP1* | Upregulation | Down 41 , 43 |
NF‐κB* | Upregulation | Down 7 , 41 |
TNF‐α | Upregulation | Down 49 , 50 , 51 , 52 |
GREM1* | Upregulation | Down (present study) |
STAT1* | Upregulation | Down 45 |
NOS3 | Upregulation | Down 53 , 54 |
CASP8 | Upregulation | Down 40 |
MAP 2 K1 | Upregulation | Down 46 |
PTEN | Upregulation | Up 36 |
IL‐2 | Upregulation | Up 55 |
BMP7 | Upregulation | Up 36 |
MIP‐ α | Upregulation | Up/down 48 , 52 |
SPARC | Upregulation | Up 56 |
NRPI | Upregulation | Up 57 |
Downregulation of genes/pathways observed in the present study as well.